Oral anticoagulation is pivotal in the management of thromboembolic risk in non-valvular
atrial fibrillation (NVAF) patients. Effective anticoagulation is important to avoid major …

Background and Objectives Nonvitamin K antagonist oral anticoagulants (NOACs) require
stricter medication adherence. We investigated the NOACs adherence in real-world practice …

Background In comparison to warfarin, non–vitamin K antagonist oral anticoagulants (NOAC
s) have the advantages of ease of dosing, fewer drug interactions, and lack of need for …

Approximately half of patients with atrial fibrillation and with risk factors for stroke are not
treated with oral anticoagulation (OAC), whether it be with vitamin K antagonists (VKAs) or …

Oral anticoagulation (OAC) is highly effective preventing stroke and mortality in AF, but
withdrawal is common in the elderly, when high bleeding risk and when are difficulties …

Atrial fibrillation (AF) is a growing public health concern and remains an independent risk
factor for ischemic stroke. Warfarin, a commonly used oral anticoagulant, is associated with …

BACKGROUND: Non-vitamin K antagonist oral anticoagulants (NOACs) are widely used for
prevention of stroke secondary to nonvalvular atrial fibrillation (NVAF). Increased use of …

Aims To investigate the association between adherence to non-vitamin K antagonist oral
anticoagulant (NOAC) and clinical outcomes and to determine the optimal cut-off level of …

Adherence to non-vitamin K antagonist oral anticoagulants (NOACs) is an important factor
for ensuring efficacy and safety in nonvalvular atrial fibrillation (NVAF). There are …

Abstract Purpose Direct oral anticoagulants (DOACs) have been promoted in patients with
nonvalvular atrial fibrillation (nv‐AF) as a more convenient alternative to vitamin K …